AN2 Therapeutics, Inc. financial data

Symbol
ANTX on Nasdaq
Location
1800 El Camino Real, Suite D, Menlo Park, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 875 % -58.8%
Debt-to-equity 11.3 % +7.61%
Return On Equity -48 % +12.3%
Return On Assets -43.1 % +13%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.3M shares -8.43%
Common Stock, Shares, Outstanding 27.4M shares -8.22%
Entity Public Float 41.1M USD -62.2%
Weighted Average Number of Shares Outstanding, Basic 30.2M shares +1.17%
Weighted Average Number of Shares Outstanding, Diluted 30.2M shares +1.17%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.6M USD -56.2%
General and Administrative Expense 14.6M USD -3.08%
Operating Income (Loss) -41.4M USD +41.9%
Net Income (Loss) Attributable to Parent -37.4M USD +42.2%
Earnings Per Share, Basic -1 USD/shares +43.1%
Earnings Per Share, Diluted -1 USD/shares +43.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18.2M USD -31.9%
Cash, Cash Equivalents, and Short-term Investments 95.3M USD -16%
Assets, Current 67.5M USD -37.2%
Other Assets, Noncurrent 0 USD -100%
Assets 75.8M USD -30.1%
Accounts Payable, Current 2.11M USD +12.1%
Employee-related Liabilities, Current 1.2M USD -34.8%
Accrued Liabilities, Current 2.95M USD -49.4%
Liabilities, Current 10M USD -32.5%
Liabilities 6.98M USD -31%
Accumulated Other Comprehensive Income (Loss), Net of Tax 25K USD
Retained Earnings (Accumulated Deficit) -223M USD -20.2%
Stockholders' Equity Attributable to Parent 68.8M USD -30%
Liabilities and Equity 75.8M USD -30.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.6M USD +39.6%
Net Cash Provided by (Used in) Financing Activities 65M USD +18525%
Net Cash Provided by (Used in) Investing Activities 9.19M USD -65%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 27.4M shares -8.22%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.37M USD -115%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.2M USD -31.9%
Deferred Tax Assets, Valuation Allowance 58.1M USD +39%
Deferred Tax Assets, Gross 58.1M USD +39%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37.3M USD +42.2%
Operating Lease, Liability, Current 13K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 28.7M USD +38%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.08M USD +42.6%
Additional Paid in Capital 292M USD +2.75%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 7.73M USD -15.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%